John Bailey - G1 Therapeutics President CEO
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
CEO
John Bailey is President CEO of G1 Therapeutics
| Age | 59 |
| Phone | 919 213 9835 |
| Web | https://www.g1therapeutics.com |
John Bailey Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Bailey against G1 Therapeutics stock is an integral part of due diligence when investing in G1 Therapeutics. John Bailey insider activity provides valuable insight into whether G1 Therapeutics is net buyers or sellers over its current business cycle. Note, G1 Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell G1 Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Bailey over six months ago Disposition of 2592 shares by John Bailey of G1 Therapeutics at 3.1189 subject to Rule 16b-3 | ||
John Bailey over six months ago Disposition of 7662 shares by John Bailey of G1 Therapeutics at 2.5077 subject to Rule 16b-3 | ||
John Bailey over six months ago Disposition of 37258 shares by John Bailey of G1 Therapeutics at 4.7888 subject to Rule 16b-3 |
G1 Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.192) % which means that it has lost $0.192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0901) %, meaning that it created substantial loss on money invested by shareholders. G1 Therapeutics' management efficiency ratios could be used to measure how well G1 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.G1 Therapeutics currently holds 57.17 M in liabilities with Debt to Equity (D/E) ratio of 1.24, which is about average as compared to similar companies. G1 Therapeutics has a current ratio of 4.66, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about G1 Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 14 records | CEO Age | ||
| Denise ScotsKnight | Mereo BioPharma Group | 66 | |
| Jeremy MBA | Day One Biopharmaceuticals | 54 | |
| Craig Collard | Heron Therapeuti | 59 | |
| Frank BeduAddo | PDS Biotechnology Corp | 60 | |
| Carole MD | Larimar Therapeutics | 66 | |
| Pascal DVM | Atara Biotherapeutics | 61 | |
| Paula Ragan | X4 Pharmaceuticals | 55 | |
| Scott Wolchko | Fate Therapeutics | 55 | |
| Scott MD | MacroGenics | 73 | |
| Malte MD | Hookipa Pharma | 63 | |
| Daniel MBA | Acumen Pharmaceuticals | 55 | |
| Kathryn MBA | Blueprint Medicines Corp | 49 | |
| JD Esq | Annexon | 57 | |
| Steven MD | Sana Biotechnology | 55 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 |
G1 Therapeutics Leadership Team
Elected by the shareholders, the G1 Therapeutics' board of directors comprises two types of representatives: G1 Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GTHX. The board's role is to monitor G1 Therapeutics' management team and ensure that shareholders' interests are well served. G1 Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, G1 Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Monica Thomas, General Officer | ||
| Jay Strum, Chief Scientific Officer | ||
| Andrew Perry, Chief Officer | ||
| Jeff Macdonald, Head of Investor Relations/Public Relations | ||
| Jennifer CPA, Chief Officer | ||
| Alexander MS, VP Operations | ||
| John V, Chief Officer | ||
| ChB MB, Chief RD | ||
| Terry MSc, Chief Officer | ||
| John Bailey, President CEO | ||
| William Roberts, Vice Communications | ||
| Mark Avagliano, Chief Officer | ||
| Evan MBA, Vice Marketing | ||
| Terry Murdock, Senior Vice President - Development Operations |
GTHX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is G1 Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.77) % | |||
| Operating Margin | (0.21) % | |||
| Current Valuation | 364.46 M | |||
| Shares Outstanding | 52.76 M | |||
| Shares Owned By Insiders | 10.92 % | |||
| Shares Owned By Institutions | 54.61 % | |||
| Number Of Shares Shorted | 3.41 M | |||
| Price To Earning | (1.95) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges |